Answers are grounded in this paper and cite their sources.
HORMONES are generally released episodically, yet to our knowledge no attempt has been made to design drugs for treating hormone deficiencies that imitate or amplify the endogenous oscillators governing pulsatile hormone release. For example, although GH is normally secreted in a pulsatile manner with peaks occurring approximately every 3 h, GH deficiency is treated by injecting recombinant GH either once daily or every 3 days. Clearly, this dosing regimen does not result in a physiological GH profile and urges the development of a more natural approach for the treatment of GH deficiency. For convenience to the patient, a pathway was sought that could be activated by a drug given orally once daily. By design, conventional peptides were excluded, because the molecular template had to be readily manipulable for optimization of oral absorption and pharmacokinetics. A receptor that controlled GH release by interaction with an endogenous small molecule was unknown, necessitating a heterodox approach to drug discovery. This reverse pharmacology involved: 1) establishing assays for the functional endpoint, stimulation of episodic GH release; 2) understanding at the cellular level how known peptides controlled GH release so that new specific targets of intervention could be selected; 3) identifying selective GH secretagogues of appropriate structure for optimization of pharmacokinetic properties; 4) characterizing and cloning the receptor for these ligands; and 5) identifying the receptor’s natural ligand. This review provides a summary of points 1–4, focusing on the discovery and properties of new GH secretagogues. These molecules were subsequently shown to be peptide mimetics of the GH-releasing peptides (GHRPs) first identified by the pioneering work of Bowers, Momany, and colleagues (1–3); for a comprehensive review of GHRPs the reader is referred to Refs. 4–9. The natural ligand for the receptor activated by GHRPs and its peptidomimetics remains elusive, but now that the receptor has been cloned and distributed, we anticipate its ligand will soon be discovered.
No takes yet. Share an insight, caveat, or question.
R G Smith (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: